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Research Protocol: David le Roux 
Registrar, Department of Paediatrics 
082 372 8449 
DrDaveleRoux@gmail.com 
 
Principle Investigator: Heather Zar  
 
Study Title: Impact of Isoniazid Preventative Therapy on Incidence of Bacteraemia in a 
Cohort of HIV-Infected Children in South Africa. 
 
Research Question: 
Is there a difference in the incidence of bacteraemias between children using Isoniazid 
Preventive Therapy (IPT) versus placebo?  
 
Rationale: 
Background: From November 2002 till December 2006, a placebo-controlled, 
randomized trial investigated the incidence of tuberculosis and the overall 
mortality in a cohort of HIV-infected children in Cape Town, South Africa.  They 
were randomized to receive either Isoniazid Preventive Therapy (IPT) or 
placebo.  In addition, they were randomized to receive 
trimethoprim/sulfamethoxaxole prophylaxis on either a daily or a three-times-
per-week schedule.  This will be a secondary analysis of the cohort looking 
specifically at the incidence of invasive bacterial infections.   
 
Aim: To describe the incidence of bacteraemia, and the spectrum of organisms 
cultured.  To determine if there was a difference in the incidence of bacteraemia 
between children using Isoniazid Preventive Therapy (IPT) versus placebo; and to 
determine if there was a difference in the incidence of bacteraemias between the 
groups using daily versus thrice-weekly trimethoprim/sulphamethoxazole prophylaxis. 
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Methods: 
Study Design: Prospective, placebo-controlled, randomized trial, designed to 
detect a difference in the incidence of Tuberculosis.  The primary outcome has 
been published, and an limited data set has been made available for analysis of 
the blood culture results. 
      
Population: 
Sample Size: 324 
Inclusion and Exclusion Criteria: All children enrolled in the original trial are 
included in this secondary analysis.  
Gender, Age and Locale: Males and females, age range from 4 weeks to 12 
years old, living in Cape Town, South Africa 
      
Disclosure/Consent Process: 
Description of the Consent Process: Signed informed consent was obtained 
from the parent or legal guardian of the child before enrolment 
 
Safety Monitoring: 
Trial is already terminated so no further safety monitoring is required 
 
Confidentiality Assurances: 
Data Security: I have received abstracted data sets with no personal identifiers 
 
Collaborative Agreements: 
The trial was run at 2 sites in Cape Town, South Africa.  The Principle 
Investigators are based at University of Stellenbosch and the University of Cape 
Town. 
Letter(s) of Collaboration: I have letters of authorization from both of the 
Principle Investigators to allow me to access the abstracted data set. 
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Prof Heather Zar, University of Cape Town and Prof Mark Cotton, University of 
Stellenbosch  
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Bacteraemia in HIV-infected children in Africa: a literature review 
David M le Roux 
 
Background 
 
Bacterial infections are a major cause of morbidity and mortality among HIV-infected 
adults[1] and children.[2]  Opportunistic infections in children are a marker of immune 
suppression, as well as a driver of further immunological decline.[3]  HIV-infected 
children are at increased risk for both superficial (skin, otitis) and invasive bacterial 
infections.[4]   Children with acute disease complicated by bacteraemia have high 
morbidity and mortality.[5]   
 
Similarly to HIV-infected adults, children have impaired clonal maturation of T helper 
1 lymphocytes, with defective interleukin-2 and interferon gamma production, 
resulting in increased susceptibility to intracellular organisms, viruses and 
malignancy. [4, 6] All children have poor immune responses to bacterial 
polysaccharide antigens in the first 2 years of life. In HIV-infected children, B-
lymphocyte dysfunction produces non-specific polyclonal immunoglobulin instead of 
functional antigen-specific antibodies.[5, 7, 8]  In addition, decreased natural killer 
cell activity and impaired neutrophil bactericidal function result in particular 
predisposition to infection with encapsulated bacteria such as Streptococcus 
pneumoniae.[4]  This increased susceptibility to pneumococcal septicaemia was 
described early in the HIV epidemic, with risk of bacteraemia increased 10 to 40 
times in HIV-infected children compared to age-matched, HIV-uninfected children.[9]  
 
Children with severe malnutrition also have impaired immunity and are at increased 
risk of bacteraemia.[10, 11]  Many HIV-infected children suffer from severe 
malnutrition [12], which further increases susceptibility to invasive bacterial 
infections.[2] 
 
Invasive disease due to Streptococcus pneumoniae and Haemophilus influenzae 
type B (HIB) may be prevented by vaccination.  HIV-infected children have less 
robust immune response to vaccination.[13, 14]  The risk of HIB vaccine failure in 
HIV-infected children not receiving anti retroviral therapy is estimated to be 35 times 
greater than HIV-uninfected children.[15]  Coverage of these vaccines remains low: 
the World Health Organisation estimated in 2008 that  in African countries, only 43% 
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of the children under 1 year received HIB vaccination, and only 1 African country was 
routinely providing pneumococcal conjugate vaccine.[16]  
 
A recent systematic review and meta-analysis of community-acquired bloodstream 
infections in Africa showed that bacteraemia was more common in Africa than in 
many industrialized countries.[17]  The authors demonstrated that in tropical 
countries, bacteraemia and malaria parasitaemia often coexist.  There is a wide 
variation in incidence rates and causative organisms across Africa.  That review 
analysed results from studies that included both HIV-infected and uninfected African 
adults and children. Due to stringent selection criteria, only 6 studies that included 
HIV-infected children were presented; none of the children were receiving highly 
active antiretroviral therapy (HAART).   
 
The impact of (HAART) on the incidence and outcomes of bacteraemia in HIV-
infected children in Africa has not yet been described.   
 
Objectives  
 
This literature review focuses on bacteraemia among HIV-infected children in Africa.  
The objectives are: to describe the prevalent organisms causing bacteraemia; to 
identify potential predictors of bacteraemia; and to evaluate the effect of HIV infection 
on risk of bacteraemia; and effect HIV infection on case fatality ratios.   
 
The incidence of bacteraemia in African children with HIV is compared to that 
described in Europe and North America during the pre-HAART era. The paucity of 
data regarding HAART and bacteraemia in Africa is discussed, and the impact of 
HAART on incidence and type of bacteraemia is examined, with a discussion on how 
the evidence from North America and Europe might apply to Africa.  
 
Search strategy 
 
The literature search was limited to English-language articles in MEDLINE 
(www.ncbi.nlm.nih.gov), using two search strings:  
“Africa and (bacteraemia OR bloodstream infection)”  
“(bacteraemia OR bloodstream infection) AND (child OR pediatric) AND (HIV OR 
AIDS)” 
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Results were limited to humans.  “Children” were defined as less than 18 years old.  
Article abstracts were obtained and reviewed. Abstracts that included only neonates, 
only adults, or children with only haematological/oncological disease were excluded.   
Sickle cell disease is prevalent in West and Central Africa, and is a known risk factor 
for invasive bacterial disease.  However for the purpose of this review, papers that 
dealt exclusively with sickle cell disease and not HIV infection were not considered 
for inclusion.  Papers reporting only malaria without bacteraemia were also rejected.  
Laboratory-based articles that dealt only with microbiology but did not have any 
clinical information were excluded.  Letters, comments, guidelines and treatment 
protocols were excluded.  Articles that reported a patient cohort that was already 
included in a larger or more comprehensive study were excluded.  The remaining 
articles were retrieved and reviewed in full text, and the same criteria applied, figure 
1.  Reference lists of all full text articles reviewed were screened for other possible 
articles.  Conference abstracts, grey literature and unpublished reports were not 
included. 
 
Diagnosis of tuberculosis is difficult in children; as most children have paucibacillary 
pulmonary disease or primary lymph node disease, mycobacterial blood culture has 
traditionally been considered to have low yield.[18] Furthermore, there is a rapidly 
expanding field of research focusing on novel methods of tuberculosis diagnosis.[19] 
Thus articles that focused solely on mycobacterial culture were not included.  
 
Quality criteria for study entry were less stringent than in the systematic review by 
Reddy et al.[17]  Studies were included even if incidence of bacteraemia was an 
incidental finding and not the a priori outcome of the research.  The major criterion for 
inclusion was that all included articles had to present raw numbers of HIV-infected 
children who had bacteraemia, separately from adults or HIV-uninfected children.  
Studies were rejected if they presented only the background prevalence of HIV-
infection in the study population or in the region.  Many studies were retrospective 
reviews.  Articles had widely varying approaches to distinguishing pathogens from 
contaminants, but no article was excluded solely on the basis of the interpretation of 
contamination.   
 
As study methodology and reporting varied significantly between reports, a meta-
analysis of the data was not feasible. 
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Results 
The online database search was done on 23 August 2010.  The two search strings 
yielded 722 articles (Fig 1).  Forty articles were reviewed in full text and 21 were 
included in the analysis.  The 21 studies were done in 8 countries in Southern and 
East African (Kenya, Malawi, Mozambique, South Africa, Tanzania, Uganda, Zambia 
and Zimbabwe).  No studies from Central, West or North Africa were found that met 
the inclusion criteria.  Two studies were conducted in rural hospitals; the other 19 
were conducted in urban centres and academic hospitals.  The data was collected 
between 1993 and 2007, table 1.  In 5 prospective studies the main outcome under 
investigation was incidence of bacteraemia.[2, 18, 20-22]  In 10 prospective studies 
the incidence of bacteraemia was a secondary outcome; primary outcomes for these 
studies included malaria, pneumonia, anaemia, opportunistic infections and efficacy 
of cotrimoxazole (CTX) preventive therapy.[23-32]. There were 4 record reviews of 
infections by specific organisms, namely meningococcal disease [33] Shigella [34], 
Streptococcus pneumoniae [35], and Pseudomonas.[36]  There were 2 retrospective 
case-note reviews: one on diarrhoea admissions and one on bacterial infections in 
hospitalised HIV-infected children.[37, 38]     
 
There were 922 bacteraemias detected in 3619 HIV-infected children.  The most 
common Gram-positive isolates were S. pneumoniae followed by Staphylococcus 
aureus; the most common Gram negative isolates were non-typhoidal Salmonellae 
(NTS).  In 5 studies[18, 20, 21, 27, 30] NTS was reported to be the most common 
organism.   
 
Of the 16 studies that included both HIV-infected and uninfected children, 14 studies 
calculated some measure of excess risk of bacteraemia among HIV-infected 
children.  Two retrospective studies showed decreased risk of bacteraemia among 
HIV-infected children.  Children with HIV were 0.66 times as likely to have Shigella 
bacteraemia[34], and 0.55 times as likely to have Pseudomonas bacteraemia[36]. All 
of the prospective studies showed increased risk of bacteraemia in HIV-infected 
children, from 1.4 [18] to 15 [37] times greater than HIV-uninfected children.  
 
Four studies used the size of the population served by the hospital to calculate a 
population-level incidence rate of bacteraemia.  In rural Kenya, an incidence rate of 
505 bacteraemias per 100 000 persons per year for children under 5 years was 
reported.[2]  In this context, HIV-infected children had a 3.3 times increased odds of 
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any bacteraemia when compared to HIV-uninfected children.  In urban 
Johannesburg, South Africa, HIV-infected children under 2 years had an incidence 
rate of 1844 pneumococcal bacteraemias per 100 000 persons per year, while HIV-
uninfected children had an incidence rate of 5 per 100 000 persons per year, giving a 
37-fold increase in incidence.[23]  In a subsequent study in the same area, the 
increase in relative risk of bacteraemia due to HIV infection ranged from 13.4 for 
Salmonella bacteraemia to 97.9 for E. coli bacteraemia.[9]  In a retrospective review 
of meningococcal reporting in Gauteng, South Africa, HIV infection conferred a 61-
times increased risk of meningococcal bacteraemia.[33]    
 
Two longitudinal cohort studies of HIV-infected children reported incidence rates of 
bacteraemia: 2.3 per 100 person-years in Zambia[27] and 7.0 per 100 person-years 
in Cape Town, South Africa.[32]  In both cases, bacteraemia was not an a priori 
objective of the study, but was detected incidentally during clinical management of 
acute illness. These estimates may therefore under-estimate the actual incidence 
rate of bacteraemia in those children.   
 
Three studies reported increased case fatality associated with bacteraemia, but no 
significant association with HIV infection.[2, 25, 37]  Three studies reported 
significantly increased case fatality associated with both bacteraemia and HIV 
infection,[21, 22, 31] and one reported increased case fatality only among children 
who were both HIV-infected and had bacteraemia.[20]  Estimates of association with 
excess case fatality for children with bacteraemia ranged from 2.03 increase odds 
(95% CI 1.05 to 5.39) [22] to a risk ratio of 4.97 (95%CI 4.41 to 5.60)[2].   Two 
studies from Malawi reported a non-significant trend towards increased deaths 
associated with either bacteraemia or HIV infection.[18, 30]  Two studies, both 
investigating hypoxic pneumonia in South African infants and children, reported 
increased case fatality amongst HIV-infected children, but no significant association 
with bacteraemia.[25, 29]  In the study of meningococcal disease, HIV-infected 
children were more likely to have bacteraemia than meningitis; compared to children 
with meningitis, children with bacteraemia were more likely to die (OR 2.1, 95% CI 
1.1 – 3.9). [33]  Eight studies did not discuss deaths, or did not describe factors 
associated with increased risk of death.   
 
There were no studies from Africa that specifically compared the incidence of 
bacteraemia in HIV-infected children before and after starting HAART.  Of the 4 
studies that reported such incidence rate ratios, 3 were from North America and one 
 12 
from Europe. Despite quite different patient characteristics, these studies had similar 
findings, with a 70 to 89% decrease in bacteraemia observed post-HAART (incidence 
rate ratio 0.11 to 0.3), table 2. 
 
Discussion: 
 
Invasive bacterial infections are common in HIV-infected children in Africa, and are 
associated with high morbidity and mortality.  The articles assessed in this review 
demonstrate the heterogeneity of paediatric HIV care in Africa, and the wide range of 
infectious risks to which African children are exposed.  The excess risk of dying due 
to bacteraemia among HIV-infected children is variable, depending on the causative 
organism, the clinical setting and the geographical context of the study population.  
The studies that did not show association with mortality were in highly selected 
subgroups of children who already had significant background disease, such as 
severe malnutrition[37] or severe malarial anaemia[30], as opposed to studies 
assessing general paediatric patients.[2] 
  
There were major differences in the prevalence of different organisms, especially 
non-typhi Salmonella and S. pneumoniae.  Non-typhi Salmonella (NTS) are endemic 
in tropical Africa, with seasonal peaks in the rainy season; contamination of food and 
water is common, and it has also been suggested that person-to-person spread may 
occur in some contexts.[39] Furthermore, malaria appears to increase the risk of 
invasive NTS infection. This association might be explained by malarial trophozoite-
induced haemolysis, resulting in the release of iron, thus creating a favourable 
environment for siderophilic organisms such as Salmonella. [30, 31]   
 
The low incidence of S pneumonia and H influenzae in some studies from tropical 
countries is remarkable.  One author described in detail the difficulties in processing 
blood culture specimens in their hospital, and suggested that fastidious organisms 
would be less likely to be detected in that context.[27]  As some of the study sites in 
tropical African countries were rural and used an off-site microbiology lab, this issue 
may have confounded the relative frequency of detection of NTS and S. pneumoniae 
in these studies.  All of the studies were completed before introduction of 
pneumococcal conjugate vaccines, and many tropical countries were not using 
Haemophilus influenzae type B vaccine at the time of the study.  The infrequency of 
positive cultures of these organisms in tropical Africa probably represents under-
detection rather than absence of disease. 
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Another concern with limited microbiological support is incomplete identification of 
bacteria.  In particular, the incidence of S. aureus can be over-estimated if 
coagulase-negative staphylococci are not correctly identified.[40]  
 
There are a number of other reasons why the reported incidences might represent 
under-estimates of actual disease burden.  Blood cultures are known to be 
insensitive in detecting bacterial infection, with bacteria identified in blood culture in 
only 20-30% of patients with invasive bacterial disease.[9, 41]  Volume of blood taken 
for culture has been shown to influence the detection of bacteraemia.[2]  As it is 
difficult to draw large volumes of blood from small children, inadequate blood 
specimens may also have contributed to under-detection of bacteraemia.  
Furthermore, many children in Africa receive antibiotics before presenting to the 
health facility[2, 27] and this may also decrease the rate of positive blood cultures. In 
addition, even in carefully controlled clinical trials, with highly selected and motivated 
families with good access to health services, many deaths occur at home. [2, 27, 32] 
Despite verbal autopsies, in some cases an adequate cause of death is never 
established.  Many of these out-of-hospital deaths may be due to bacterial infections: 
in one study of post mortem blood cultures done within 3 hours of death on 212 
Zimbabwean children who died at home, 92 (43%) had positive bacterial growth, with 
the most common organism being Klebsiella. [42] 
 
There is strong and consistent association of bacteraemia and increased risk of 
death among HIV-infected children in Africa.  Some authors suggested that the 
observed increased mortality was largely due to increased incidence of 
bacteraemia.[20, 33] However, three large studies were able to demonstrate that HIV 
infection was associated with an increase in mortality independent of the incidence of 
bacteraemia.[21, 22, 31]  These three studies had enrolled many infants and young 
children (median ages 8.5, [21]  5,[22] and 11[31] months), who were at high risk of 
rapid disease progression and death without anti-retroviral therapy.[43]  These young 
children should be prioritised for provision of HAART. 
 
The decreased incidence rates of bacteraemia observed in children in the post 
HAART era in America and Europe reflect the immune restoration and increased 
survival observed in children on HAART.  However, three of the trials evaluated in 
this review are subject to the “ageing cohort” effect,[44-46] where the same children 
are followed over time.  The incidence rates of bacteraemia post-HAART are 
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compared to incidence rates that occurred in the same children before HAART was 
available.  As individual risk of bacteraemia decreases as a child gets older,[2] the 
effect of HAART may be confounded by the natural decreased incidence that would 
be expected over time.  This effect was partly resolved in one pooled analysis of 4 
birth cohorts, where follow-up time was censored at 72 months, the age when risk of 
bacteraemia starts to decrease.[5]  Thus the incidence rates of bacteraemia with and 
without HAART were compared among children of similar age; this estimated 
incidence rate ratio of 0.3 is the most conservative estimate of all of the studies, but 
is probably the most reliable quantification of the independent effect of HAART on 
bacteraemia risk.   
 
Conclusion 
 
Bacteraemia is common in HIV-infected African children, and is associated with a 
significantly increased risk of death. There is noticeable geographical variation in the 
incidence and outcome of bacteraemia, related to both local prevalence of disease 
(differences in types of bacteria, and prevalence of malaria) and capacity for the 
detection of bacteraemia.  There have been no trials investigating the effect of 
HAART on incidence of bacteraemia in Africa. However, data from North America 
and Europe suggest that HAART confers a 70-89% decreased risk of bacteraemia in 
HIV-infected children.  This is an issue that should be prospectively evaluated, and 
should strengthen the call to expand anti-retroviral program coverage to children in 
Africa. 
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Tables and figures 
 
Fig 1: Selection of eligible articles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Search string 2: 
 “(bacteraemia OR bloodstream infection) AND (child OR 
pediatric) AND (HIV OR AIDS)” 
193 titles screened 
 
Excluded if only adult, non human, non-African, only parasites / 
malaria – 108 abstracts obtained 
 
 
 
Excluded if only neonatal, haematology/oncology, sickle cell disease; only adults; no HIV; not in Africa; only 
microbiological with no clinical information; letters, comments on other articles, treatment guidelines 
 
Excluded if only adult, non human, only parasites / malaria – 
343 abstracts obtained  
 
Search string 1: 
“Africa and (bacteraemia OR bloodstream infection)”  
529 titles screened 
 
 
40 articles reviewed in full text 
 
21 articles included for final analysis 
 
6 articles excluded as patients 
were part of larger study which 
was included 
13 articles excluded – HIV prevalence not reported 
separately: 
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Table 1. Bacteraemia among HIV-infected children in Africa. 
First 
Author 
Location, 
study dates 
Study design 
Main outcome of 
study 
Number 
of 
children 
Age 
range 
Number HIV- 
infected 
children 
Number of 
bacteraemia: 
HIV-infected vs 
HIV- uninfected 
Organisms 
Comments on case fatality 
ratio (CFR)  
Archibald 
[18] 
Lilongwe 
Malawi; 
1998 
Prospective, 
blood culture 
drawn for all 
acute 
admissions 
Predictors of 
bacteraemia 
229 Median  
2.7 years 
HIV infected: 
63/229 (28%); 
HIV uninfected 
160/229 (70%) 
Not tested: 
6/229(3%)  
 
12/63 (19%) vs 
22/160 (14%) 
NTS, E. coli Neither bacteraemia nor 
HIV affected CFR (data not 
given) 
 
Bachou 
[20] 
Kampala, 
Uganda; 
2003-2004 
Blood culture 
drawn for all 
children <60 
months with 
severe 
malnutrition 
Incidence of 
bacteraemia in 
children admitted 
with malnutrition 
450 Median 
17 
months 
(range  
4-60) 
HIV infected: 
149/450 (33%); 
HIV uninfected: 
259/450 (58%) 
Unknown: 
42/450 (9%) 
30/149 (20%) 
vs 39/259 
(15%) 
NTS, S. 
aureus 
With bacteraemia: 22/76 
(29%) died; without 
bacteraemia 85/369 (23%) 
died. Among HIV-infected 
children, 13/30 (43%) with 
bacteraemia died;  
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First 
Author 
Location, 
study dates 
Study design 
Main outcome of 
study 
Number 
of 
children 
Age 
range 
Number HIV- 
infected 
children 
Number of 
bacteraemia: 
HIV-infected vs 
HIV- uninfected 
Organisms 
Comments on case fatality 
ratio (CFR)  
Berkley  
[47] 
Rural 
Kenya;199
8-2002 
Blood culture 
drawn  for all 
children <13 
years 
Incidence of 
bacteraemia 
16570 0-13 
(88% 
<5yr) 
HIV infected: 
243; HIV 
uninfected: 
1838; unknown 
14483  
HIV infected: 
186/243 (77%) 
vs 908/16327 
(6%) HIV 
uninfected or 
unknown 
S 
pneumoniae, 
NTS 
With bacteraemia: 
308/1094 (28%) died; 
without bacteraemia  
876/15 476 (6%) died. 
Mortality of HIV-infected 
children not given  
Blomberg 
[21] 
Dar es 
Salaam, 
Tanzania; 
2001-2002 
Blood culture 
drawn from 
all children 
with severe 
disease** 
Incidence of 
bacteraemia in 
children 
1787 
children 
(1828 
episodes
) 
Median 
8.5 
months 
HIV infected: 
152 (9%) 
HIV uninfected: 
753 (42%)  
Unknown: 882 
(49%) 
28/160 (18%) 
admissions vs 
119/766 (16%)  
admissions 
NTS With bacteraemia: 80/229 
(35%) died; without 
bacteraemia 197/1403 
(14%) died; risk ratio 2.49 
(2.00 – 3.01). Mortality of 
HIV-infected children not 
given  
Bronzan 
[30] 
Blantyre, 
Malawi; 
1996-2005 
Prospective: 
blood culture 
drawn from 
all children 
with severe 
malaria 
Incidence of 
bacteraemia in 
severe malaria 
1388 Median 
40 
months 
HIV infected: 
178 (13%);  
HIV uninfected: 
941 (68%); 
Unknown: 269 
(19%) 
HIV infected: 
13/178 (7%) 
HIV uninfected: 
38/941 (4%) 
Unknown: 
13/269 (5%) 
NTS With bacteraemia: 9/64 
(14%) died; without 
bacteraemia   109/1323 
(8%) died; Mortality of HIV-
infected children not given 
 18 
First 
Author 
Location, 
study dates 
Study design 
Main outcome of 
study 
Number 
of 
children 
Age 
range 
Number HIV- 
infected 
children 
Number of 
bacteraemia: 
HIV-infected vs 
HIV- uninfected 
Organisms 
Comments on case fatality 
ratio (CFR)  
Chhagan 
[37] 
Durban, 
South 
Africa; 
2001 
Retrospective 
review of 
diarrhoea 
admissions  
Co-morbidity and 
CFR of diarrhoeal 
disease 
319 Median 
8.5 
months 
(IQR 4 to 
19 
months) 
HIV infected: 
214/319 (67%) 
HIV uninfected: 
103/319 (32%) 
Unknown: 
2/319 
34/194 vs 1/94  Klebsiella sp 
/ E. coli 
Children with bacteraemia:  
14/35 (40%) died; without 
bacteraemia 32/284 (11%) 
died;  
HIV infected: 42/212 (20%) 
died; HIV uninfected 4/103 
(4%) died 
Cohen 
[33] 
Gauteng, 
South 
Africa; 
2003-2007 
Review of 
meningococc
al case 
reporting 
Incidence of 
meningitis/ 
bacteraemia,  
HIV infected vs 
uninfected, all 
ages  
181 
children 
(<14); 
127 
adults 
(>15)  
Median 6 
yr (IQR 
3-25 
years) 
54/181 (30%) 54/181 (30%)  Neisseria 
meningitidis 
All patients: HIV infected: 
27/138 died (20%); HIV 
uninfected 18/170 (11%) 
died; not present children 
CFR separately 
Davies 
[34]  
Johannes-
burg, South 
Africa; 
1996-1998 
Review of all 
cases of 
Shigella 
bacteraemia 
(all ages) 
Describe risk 
factors and 
outcomes of 
Shigella 
bacteraemia 
20 
children 
(<18) ; 14 
adults 
(>18) 
Children: 
median 7 
months 
HIV infected: 
6/20 (30%) 
HIV uninfected: 
9/20 (45%) 
Unknown:5/20 
(25%) 
 
6/15 vs 9/15 Shigella 
flexneri 
No child deaths 
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First 
Author 
Location, 
study dates 
Study design 
Main outcome of 
study 
Number 
of 
children 
Age 
range 
Number HIV- 
infected 
children 
Number of 
bacteraemia: 
HIV-infected vs 
HIV- uninfected 
Organisms 
Comments on case fatality 
ratio (CFR)  
Jaspan 
[38] 
Cape 
Town, 
South 
Africa; 
2002-2006 
Record 
review of  
hospitalised 
HIV-infected 
children  
Describe 
bacterial disease 
and antibiotic 
sensitivity in HIV-
infected children 
141 Median 
1.2 years 
(IQR 0.5-
2.3 
years) 
141 (100%) 128 S. 
pneumoniae 
13/141 (9%) died; did not 
describe difference in case 
fatality if had bacteraemia 
Jones 
[23] 
Johannes-
burg, South 
Africa; 
1996 
Prospective 
study of S. 
pneumoniae 
infection, all 
ages 
Burden of 
disease of S. 
pneumoniae in 
HIV infected and 
uninfected 
49 
children 
(<13); 
127 
adults 
(>13)  
2 weeks 
to 12 
years 
25/49 (51%) 25 vs 24  S. 
pneumoniae 
HIV infected: 2/25 (8%) 
died; HIV uninfected 1/24 
(4%); risk ratio 1.9 (0.19-
19.8)   
Karstaedt 
[35] 
Johannes-
burg, South 
Africa; 
1996-1997 
Retrospective  
review of S. 
pneumoniae 
bacteraemia 
Determine 
incidence of S 
pneumoniae 
bacteraemia 
194  HIV infected:  
67; HIV 
uninfected: 44; 
Unknown: 83 
HIV infected:  
67; HIV 
uninfected: 44; 
Unknown: 83 
S 
pneumoniae 
42/194  (22%) died, did not 
distinguish HIV infected 
from HIV uninfected 
Lala 
[24] 
Johannes-
burg, South 
Africa; 
1997-1998 
Blood culture 
drawn on all 
children with 
pneumonia 
 
Value of CRP in 
pneumonia 
570 6 weeks 
to 5 
years 
244/570 (43%) 38/244 vs 
25/326 
S 
pneumoniae 
(Did not describe CFR) 
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First 
Author 
Location, 
study dates 
Study design 
Main outcome of 
study 
Number 
of 
children 
Age 
range 
Number HIV- 
infected 
children 
Number of 
bacteraemia: 
HIV-infected vs 
HIV- uninfected 
Organisms 
Comments on case fatality 
ratio (CFR)  
Madhi CID 
2002 
[25] 
Johannes-
burg, South 
Africa; 
2000-2001 
Blood culture 
drawn on all 
children with 
pneumonia 
Effectiveness of 
CPT for PJP 
prophylaxis 
185 Median 
4.5 
months 
185 (100%) 18 
bacteraemias 
in 231 episodes 
of pneumonia 
S 
pneumoniae 
Among children with proven 
PJP, higher CFR if also had 
bacteraemia: 2/20 with 
bacteraemia died vs 3/78 
without bacteraemia; risk 
ratio 3.9 (0.85 – 17.9)  
Madhi CID 
2000 
[9] 
Johannes-
burg, South 
Africa; 
1997-1998 
Blood culture 
drawn on all 
children with 
severe 
pneumonia 
Aetiology and 
outcomes of 
pneumonia 
 
1215 2-59 
months 
HIV infected: 
548 / 1215 
(45%); HIV 
uninfected 
617/1215 
(51%); 
unknown 
50/1215 (4%) 
HIV infected 
82/548 (15%) 
vs 40/617 (6%) 
in HIV 
uninfected 
S 
pneumoniae 
HIV infected children with 
bacteraemia: 14/82 (17%) 
died: HIV infected children 
without bacteraemia 58/466 
(12%) died; risk ratio 1.4 
(0.80 – 2.34)   
Mulenga 
[27] 
Lusaka, 
Zambia; 
2001-2003 
RCT of CTX 
vs placebo in 
HIV-infected 
children 
Survival and 
bacterial 
infections 
comparing CTX 
vs placebo 
534 Median 
4.4 years 
at 
baseline 
(36% 
<2yr) 
534 (100%) 14/534 
(2.3/100PY) 
NTS 186 (35%) died; did not 
describe difference in 
mortality if children had 
bacteraemia or not 
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First 
Author 
Location, 
study dates 
Study design 
Main outcome of 
study 
Number 
of 
children 
Age 
range 
Number HIV- 
infected 
children 
Number of 
bacteraemia: 
HIV-infected vs 
HIV- uninfected 
Organisms 
Comments on case fatality 
ratio (CFR)  
Nathoo 
[22] 
Harare, 
Zimbabwe; 
1993-1994 
Blood culture 
drawn on all 
pyrexial 
children <8 
years 
Incidence of 
community 
acquired 
bacteraemia 
309 Median 5 
months 
168/309 (54%) 67/168 (40%) 
vs 28/141 
(20%) 
S. aureus, S 
pneumoniae 
Among HIV infected 
children: 20/67 (30%) with 
bacteraemia died, vs 
18/101 (18%) without 
bacteraemia; risk ratio 1.67 
(0.96 – 2.92) 
 
Perovic 
[36] 
Johannes-
burg, South 
Africa; 
1998-1999 
Review of all 
cases of 
Pseudomonas 
aeruginosa 
Describe risk 
factors and 
outcomes  
38 
children  
44 adults 
(Not 
stated) 
12/38 (32%) 12/38 (32%) vs 
22/38 (68%) 
Pseudomon
as 
aeruginosa 
Described increased case 
fatality among HIV-infected 
adults with bacteraemia; did 
not describe case fatality in 
HIV-infected children 
 
Sigauque 
[31] 
Rural 
Mozam-
bique; 
2004-2006 
Blood 
cultures 
drawn on all 
children <2 
years 
Characteristics of 
children with 
severe 
pneumonia 
 
757 0-23 
months  
HIV infected: 
53/757 (7%); 
HIV uninfected: 
149/202 (20%); 
unknown 
555/757 (73%) 
 
10/39 (26%) vs 
14/111 (13%)  
S. 
pneumoniae  
Children with bacteraemia 
15/58 (26%) died, children 
without bacteraemia 62/497 
(12%) died;  
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First 
Author 
Location, 
study dates 
Study design 
Main outcome of 
study 
Number 
of 
children 
Age 
range 
Number HIV- 
infected 
children 
Number of 
bacteraemia: 
HIV-infected vs 
HIV- uninfected 
Organisms 
Comments on case fatality 
ratio (CFR)  
Westwood 
[28] 
Cape 
Town, 
South 
Africa; 
1996 
Cohort of 
HIV-infected 
children 
followed for 1 
year 
Incidence of 
bacterial 
infections 
108 Median 
16 
months 
108 (100%) 31 S. 
pneumoniae 
No deaths reported 
Zar  
Acta Paed 
2001 
[29] 
Cape 
Town, 
South 
Africa; 
1998 
Prospective 
study of 
children 
admitted with 
severe 
pneumonia 
Aetiology and 
outcome of HIV-
infected children 
with pneumonia 
250 Median 6 
months 
151 (60.4) HIV infected 
20/151 (13%) 
vs 15/99 (15%) 
HIV uninfected 
S. 
pneumoniae 
HIV infected 31/151 (21%) 
died vs 8/99 (8%) HIV 
uninfected; did not describe 
CFR for children with 
bacteraemia 
Zar  
AIDS 2010 
[32] 
Cape 
Town, 
South 
Africa; 
2003-2007 
Prospective 
study of CPT 
HIV-infected 
children; 
blood 
cultures 
drawn when 
clinically 
indicated 
Mortality and 
morbidity on 
intermittent vs 
daily CTX 
prophylaxis 
324 Median 
22 
months 
at 
baseline 
324 (100%) 30 children had 
47 episodes of 
bacteraemia   
S. 
pneumoniae 
Children with bacteraemia: 
13/30 (43%) died vs 40/294 
(14%) without bacteraemia; 
Risk ratio 3.18 (1.93 to 
5.25). 
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vs = versus 
*NTS = Non-typhoid Salmonella  
**PJP = Pneumocystis jirovecii pneumonia 
CTX = co-trimoxazole  
CPT – co-trimoxazole preventive therapy 
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Table 2: Impact of HAART on incidence of bacteraemia in HIV-infected children  
 
1st Author Location; study 
date 
Study 
design 
Number 
of 
patients 
Age range Main outcome measure Incidence of bacteraemia 
pre- vs post-HAART; 
incidence rate ratio 
 
Gona 
[44] 
PACTG 219C sites in 
USA and Puerto 
Rico; 2000-2004 
Prospective 2767 Median 9.9 
years; 
disenrolled 
when age 24 
years 
Incidence of opportunistic 
infections in children on 
HAART compared to a pre-
HAART study (Dankner 2001) 
Pre: 3.3 / 100PY 
Post: 0.35 / 100PY 
IRR 0.11 
Guellin 
[45] 
Madrid, Spain; 1990-
2006 
Retrospective 
review of 
clinical cohort  
366 Median 2.6 
years at 
enrollment 
Incidence of opportunistic 
infections in three calendar 
periods 
Pre:  2.85 /100PY  
Post: 0.36 /100PY  
IRR 0.13 
Kapogiannis 
[5] 
4 cities in USA; 
Enrolled 1986 to 
1990; ended follow 
up 2004 
Longitudinal 
data from 
birth 4 
cohorts 
364 Birth to 72 
months 
Incidence rate of bacteraemia 
pre vs post HAART 
Pre: 9.8  / 100PY 
Post: 3  / 100PY 
IRR 0.3 
Steenhoff 
[46] 
Philadelphia, USA; 
1989-2006 
Retrospective 
record review 
256 Med 1.1years 
(range birth 
to 18 years) 
Incidence of invasive 
pneumococcal disease pre-
HAART and pre PCV 
Pre: 1.86 / 100 PY 
Post: 0.29  / 100PY 
IRR 0.16 
*IRR = incidence rate ratio 
**PCV = Pneumococcal conjugate vaccine 
 
 25 
References 
 
1. Anglaret X, Eholie S. Prophylaxis with co-trimoxazole for HIV infected adults 
in Africa. Bmj 2008;337:a304. 
2. Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, Mwarumba S, et al. 
Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 
2005;352:39-47. 
3. Dankner WM, Lindsey JC, Levin MJ. Correlates of opportunistic infections in 
children infected with the human immunodeficiency virus managed before highly 
active antiretroviral therapy. Pediatr Infect Dis J 2001;20:40-8. 
4. Hatherill M. Sepsis predisposition in children with human immunodeficiency 
virus. Pediatr Crit Care Med 2005;6:S92-8. 
5. Kapogiannis BG, Soe MM, Nesheim SR, Sullivan KM, Abrams E, Farley J, et 
al. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era 
among HIV-infected children in the US Perinatal AIDS Collaborative Transmission 
Study (1986-2004). Pediatrics 2008;121:e1229-39. 
6. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. 
Part 1: cellular and humoral immune responses. Ann Intern Med 2001;134:761-76. 
7. Bernstein LJ, Ochs HD, Wedgwood RJ, Rubinstein A. Defective humoral 
immunity in pediatric acquired immune deficiency syndrome. J Pediatr 
1985;107:352-7. 
8. Schnittman SM, Lane HC, Higgins SE, Folks T, Fauci AS. Direct polyclonal 
activation of human B lymphocytes by the acquired immune deficiency syndrome 
virus. Science 1986;233:1084-6. 
9. Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP. Increased disease 
burden and antibiotic resistance of bacteria causing severe community-acquired lower 
respiratory tract infections in human immunodeficiency virus type 1-infected children. 
Clin Infect Dis 2000;31:170-6. 
10. Berkowitz FE. Pneumococcal bacteraemia--a study of 75 black children. Ann 
Trop Paediatr 1981;1:229-35. 
11. Berkowitz FE. Bacteremia in hospitalized black South African children. A 
one-year study emphasizing nosocomial bacteremia and bacteremia in severely 
malnourished children. Am J Dis Child 1984;138:551-6. 
12. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, et al. Effect 
of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with 
HIV: randomised controlled trial. Bmj 2007;334:136. 
13. Madhi SA, Adrian P, Cotton MF, McIntyre JA, Jean-Philippe P, Meadows S, 
et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and 
qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect 
Dis 2010;202:355-61. 
14. Mangtani P, Mulholland K, Madhi SA, Edmond K, O'Loughlin R, Hajjeh R. 
Haemophilus influenzae type b disease in HIV-infected children: a review of the 
disease epidemiology and effectiveness of Hib conjugate vaccines. Vaccine 
2010;28:1677-83. 
15. Madhi SA, Kuwanda L, Saarinen L, Cutland C, Mothupi R, Kayhty H, et al. 
Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate 
vaccine in HIV infected and uninfected African children. Vaccine 2005;23:5517-25. 
 26 
16. WHO vaccine-preventable diseases:monitoring system 2009 global summary. 
2009.http://whqlibdoc.who.int/hq/2009/WHO_IVB_2009_eng.pdf. 21 November 
2010 
17. Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream 
infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis 
2010;10:417-32. 
18. Archibald LK, Kazembe PN, Nwanyanwu O, Mwansambo C, Reller LB, 
Jarvis WR. Epidemiology of bloodstream infections in a bacille Calmette-Guerin-
vaccinated pediatric population in Malawi. J Infect Dis 2003;188:202-8. 
19. Zar HJ, Connell TG, Nicol M. Diagnosis of pulmonary tuberculosis in 
children: new advances. Expert Rev Anti Infect Ther 2010;8:277-88. 
20. Bachou H, Tylleskar T, Kaddu-Mulindwa DH, Tumwine JK. Bacteraemia 
among severely malnourished children infected and uninfected with the human 
immunodeficiency virus-1 in Kampala, Uganda. BMC Infect Dis 2006;6:160. 
21. Blomberg B, Manji KP, Urassa WK, Tamim BS, Mwakagile DS, Jureen R, et 
al. Antimicrobial resistance predicts death in Tanzanian children with bloodstream 
infections: a prospective cohort study. BMC Infect Dis 2007;7:43. 
22. Nathoo KJ, Chigonde S, Nhembe M, Ali MH, Mason PR. Community-
acquired bacteremia in human immunodeficiency virus-infected children in Harare, 
Zimbabwe. Pediatr Infect Dis J 1996;15:1092-7. 
23. Jones N, Huebner R, Khoosal M, Crewe-Brown H, Klugman K. The impact of 
HIV on Streptococcus pneumoniae bacteraemia in a South African population. Aids 
1998;12:2177-84. 
24. Lala SG, Madhi SA, Pettifor JM. The discriminative value of C-reactive 
protein levels in distinguishing between community-acquired bacteraemic and 
respiratory virus-associated lower respiratory tract infections in HIV-1-infected and -
uninfected children. Ann Trop Paediatr 2002;22:271-9. 
25. Madhi SA, Cutland C, Ismail K, O'Reilly C, Mancha A, Klugman KP. 
Ineffectiveness of trimethoprim-sulfamethoxazole prophylaxis and the importance of 
bacterial and viral coinfections in African children with Pneumocystis carinii 
pneumonia. Clin Infect Dis 2002;35:1120-6. 
26. Madhi SA, Venter M, Madhi A, Petersen MK, Klugman KP. Differing 
manifestations of respiratory syncytial virus-associated severe lower respiratory tract 
infections in human immunodeficiency virus type 1-infected and uninfected children. 
Pediatr Infect Dis J 2001;20:164-70. 
27. Mulenga V, Ford D, Walker AS, Mwenya D, Mwansa J, Sinyinza F, et al. 
Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in 
HIV-infected children. AIDS 2007;21:77-84. 
28. Westwood AT, Eley BS, Gilbert RD, Hanslo D. Bacterial infection in children 
with HIV: a prospective study from Cape Town, South Africa. Ann Trop Paediatr 
2000;20:193-8. 
29. Zar HJ, Hanslo D, Tannenbaum E, Klein M, Argent A, Eley B, et al. 
Aetiology and outcome of pneumonia in human immunodeficiency virus-infected 
children hospitalized in South Africa. Acta Paediatr 2001;90:119-25. 
30. Bronzan RN, Taylor TE, Mwenechanya J, Tembo M, Kayira K, Bwanaisa L, 
et al. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV 
coinfection, and outcome. J Infect Dis 2007;195:895-904. 
31. Sigauque B, Roca A, Bassat Q, Morais L, Quinto L, Berenguera A, et al. 
Severe pneumonia in Mozambican young children: clinical and radiological 
characteristics and risk factors. J Trop Pediatr 2009;55:379-87. 
 27 
32. Zar HJ, Workman L, le Roux SM, Jennings T, Jele N, Schaaf HS, et al. A 
randomized controlled trial of intermittent compared with daily cotrimoxazole 
preventive therapy in HIV-infected children. Aids 2010;24:2225-32. 
33. Cohen C, Singh E, Wu HM, Martin S, de Gouveia L, Klugman KP, et al. 
Increased incidence of meningococcal disease in HIV-infected individuals associated 
with higher case-fatality ratios in South Africa. Aids 2010;24:1351-60. 
34. Davies NE, Karstaedt AS. Shigella bacteraemia over a decade in Soweto, 
South Africa. Trans R Soc Trop Med Hyg 2008;102:1269-73. 
35. Karstaedt AS, Khoosal M, Crewe-Brown HH. Pneumococcal bacteremia 
during a decade in children in Soweto, South Africa. Pediatr Infect Dis J 
2000;19:454-7. 
36. Perovic O, Koornhof HJ, Crewe-Brown HH, Duse AG, van Nierop W, Galpin 
JS. Pseudomonas aeruginosa bacteraemia in an academic hospital in South Africa. S 
Afr Med J 2008;98:626-32. 
37. Chhagan MK, Kauchali S. Comorbidities and mortality among children 
hospitalized with diarrheal disease in an area of high prevalence of human 
immunodeficiency virus infection. Pediatr Infect Dis J 2006;25:333-8. 
38. Jaspan HB, Huang LC, Cotton MF, Whitelaw A, Myer L. Bacterial disease 
and antimicrobial susceptibility patterns in HIV-infected, hospitalized children: a 
retrospective cohort study. PLoS One 2008;3:e3260. 
39. Morpeth SC, Ramadhani HO, Crump JA. Invasive non-Typhi Salmonella 
disease in Africa. Clin Infect Dis 2009;49:606-11. 
40. Falade AG, Lagunju IA, Bakare RA, Odekanmi AA, Adegbola RA. Invasive 
pneumococcal disease in children aged <5 years admitted to 3 urban hospitals in 
Ibadan, Nigeria. Clin Infect Dis 2009;48 Suppl 2:S190-6. 
41. Saez-Llorens X, Vargas S, Guerra F, Coronado L. Application of new sepsis 
definitions to evaluate outcome of pediatric patients with severe systemic infections. 
Pediatr Infect Dis J 1995;14:557-61. 
42. Wolf BH, Ikeogu MO, Vos ET. Effect of nutritional and HIV status on 
bacteraemia in Zimbabwean children who died at home. Eur J Pediatr 1995;154:299-
303. 
43. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early 
antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 
2008;359:2233-44. 
44. Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman 
SA, et al. Incidence of opportunistic and other infections in HIV-infected children in 
the HAART era. Jama 2006;296:292-300. 
45. Guillen S, Garcia San Miguel L, Resino S, Bellon JM, Gonzalez I, Jimenez de 
Ory S, et al. Opportunistic infections and organ-specific diseases in HIV-1-infected 
children: a cohort study (1990-2006). HIV Med 11:245-52. 
46. Steenhoff AP, Wood SM, Rutstein RM, Wahl A, McGowan KL, Shah SS. 
Invasive pneumococcal disease among human immunodeficiency virus-infected 
children, 1989-2006. Pediatr Infect Dis J 2008;27:886-91. 
47. Berkley JA, llevitiallyit adults ClM. Bacteremia among children admitted to a 
rural hospital in Kenya. 2005;352:39-47. 
 
 
 28 
Abstract 
Aims 
Bacteraemia is an important cause of morbidity and mortality in HIV-infected children, 
especially in the absence of highly active anti-retroviral therapy (HAART). The 
incidence of bacteraemia in a cohort of HIV-infected children from South Africa is 
described.  
 
Methods 
HIV-infected children enrolled in a randomised controlled trial evaluating 2 regimens 
of co-trimoxazole preventative therapy (CPT) were followed for 5 years from January 
2003.  Blood cultures were taken during acute admissions, when clinically indicated. 
 
Results 
324 children were followed for 672 person-years; 364 blood cultures were taken from 
125 children.  47 bacteraemias occurred in 30 children; 22 (47%) were Gram positive 
and 25 (53%) Gram negative bacteria.  S. pneumoniae was the most common 
isolate, comprising 32% of bacteraemias.   
53 (16%) children died during the study. Children with documented bacteraemia had 
higher risk of death than those without bacteraemia (risk ratio 3.18, 95% CI 1.93 to 
5.05).  Children receiving intermittent CPT had higher incidence of bacteraemia than 
those receiving daily CPT (9.63 vs. 4.08 per 100 person-years, incidence rate ratio 
(IRR) 2.36, (95% CI 1.21 to 4.86).  Children established on HAART had lower 
incidence than those not on HAART (2.2 vs. 8.5 per 100 person years, IRR 0.26, 
95% CI 0.09 to 0.61); however, the incidence rate of bacteraemia was significantly 
higher in the first 3 months of commencing HAART compared to those not on 
HAART(IRR 3.82, 95% CI 1.84 – 7.58). 
 
Conclusion 
Bacteraemia in HIV-infected children is common and associated with high mortality; 
lower rates of bacteraemia occurred in children receiving daily CPT and in those well 
established on HAART.  
 
Keywords: 
Africa, children, HIV, bacteraemia, anti-retroviral therapy, co-trimoxazole, 
preventive therapy
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Introduction 
Invasive bacterial infections are a major cause of mortality and morbidity among HIV-
infected children in Africa.[1]  As children with HIV are particularly susceptible to 
infection with encapsulated bacteria,[2] the incidence of bacteraemia in HIV-infected 
children is 40 to 100-fold that of similar-aged HIV-uninfected children.[3]   Treatment 
with highly active antiretroviral therapy (HAART) has been shown to decrease  
mortality in many clinical trial and programmatic settings in sub-Saharan Africa[4, 5] 
with similar early treatment outcomes and immune recovery to those seen in Europe 
and North America.[4]  HAART is also associated with decreased incidence of 
bacteraemia.[2, 6, 7]  Co-trimoxazole (CTX) preventive therapy (CPT), initially used 
for prophylaxis against Pneumocystis jirovecii, decreases mortality of HIV-infected 
African children, [8] with significant reductions in bacterial infections.[9] 
 
In a cohort of HIV-infected children in Cape Town, South Africa, it was previously 
reported that, compared to daily CPT, intermittent CPT was associated with longer 
hospitalisation and increased incidence of bacteraemia. [10] The aim of this study 
was to further investigate risk factors for bacteraemia.    
 
Methods 
A prospective trial to compare different dosing schedules of CPT in HIV-infected 
children commenced in January 2003.  The study had a factorial design, with two 
levels of randomisation and hence four comparison groups: children were 
randomised to receive either daily or three times a week CPT, and then further 
randomised to receive either isoniazid (INH) or placebo on the same dosing 
schedule, figure 1.  After interim analysis showed significantly reduced mortality in 
the INH groups, the placebo arm was terminated on 17 May 2004, on the 
recommendation of the Data Safety Monitoring Board.[11]  Thereafter, all children 
receiving placebo were changed to INH, continuing the same dosing schedule (daily 
or thrice weekly) as before.  After May 2004, a further group of children were 
recruited into the study, on open-label INH and CPT, randomised to either daily or 
three times a week. The trial was run in two tertiary hospitals in Cape Town, South 
Africa (Red Cross War Memorial Children’s Hospital, University of Cape Town and 
Tygerberg Children’s Hospital, Stellenbosch University).  Blood culture results from 
January 2003 until December 2007 were analysed. 
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Participants 
Participants were HIV-infected children ≥ 8 weeks old, attending either hospital. 
Additional inclusion criteria and exclusion criteria have been described.[11]  Written 
informed consent was obtained from a parent or legal guardian.  HIV status was 
confirmed at enrolment by 2 enzyme linked immunosorbent assays (Abbott AxSYM 
HIV antibody/antigen ELISA) in children older than 15 months; in younger children, 
the polymerase chain reaction (Amplicor HIV-1, Roche Diagnostic Systems) was 
used. 
 
Medication 
Dosage of CTX was calculated at 5mg/kg/dose of the trimethoprim component.  
Dose was adjusted according to weight at each visit and rounded up to the nearest 
0.5 millilitre.  INH or placebo was given on the same dosing schedule as the CTX. 
INH was given in tablet form (100 mg tablets, Be-Tabs Pharmaceuticals, 
Johannesburg, South Africa) as quarter or half tablets, for a dose of approximately 
10mg/kg (range 8-12mg/kg). Placebo tablets were manufactured to look identical to 
INH. 
 
In 2003, HAART was not yet widely available in South Africa but was obtained for 
some children through pharmaceutical trials or charitable donations. From 2004, due 
to the HAART roll-out programme, study participants qualifying on local criteria could 
access HAART.  
 
Allocation 
Randomisation was stratified by site, to account for potential differences in study site 
population and for the benefit of precision. The trial statistician generated random 
variable block lists; study pharmacists labelled study drugs sequentially. Study 
pharmacists issued study medication at scheduled study visits. All participants and 
investigators were blinded to the placebo/INH allocation, but not to the CPT dosing 
schedule. 
 
Bacteriology 
Blood cultures were taken by emergency room or hospital ward staff at the treating 
clinician’s discretion.  Details of a hospital admission were recorded by a study team 
member and all blood results were followed up in person or telephonically. Children 
were admitted to the tertiary academic study hospitals or their affiliated secondary-
level (community) hospitals. Indications for blood cultures are similar in these 
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hospitals and include clinical sepsis, suspected bacterial meningitis, pyrexia <3 
months old, severe malnutrition requiring admission, spiking fever or severe 
pneumonia.  Cultures were drawn in a sterile manner according to written hospital 
protocols. Cultures were taken in Bactec Peds Plus/F bottles (Becton-Dickenson) 
and incubated in the Bactec 9240 blood culture system.  Isolates from positive blood 
cultures were identified and had susceptibility testing performed according to 
standard laboratory practices in the two laboratories serving the respective hospitals.  
As most children were recruited during or soon after hospital admission, and due to 
the frequent hospitalisations of children in the study, differences between community-
acquired and hospital-acquired bacteraemias were not explored.  When isolates of 
coagulase-negative staphylococcus, micrococcus or viridans streptococcus were 
detected, the records were reviewed to determine if this was a likely contaminant or 
pathogen.  In no children were these bacteria cultured repeatedly, or in a context 
suggestive of endocarditis or central line infection.  They were therefore regarded as 
contaminants.  Cultures that grew other organisms were considered indicative of 
bacteraemia. Blood cultures with no reported growth after 5 days were considered 
negative.  Children were managed according to hospital antibiotic guidelines; 
antibiotic choices were amended once susceptibility results were known.  Bacterial 
resistance is reported for the most commonly used antibiotics, or those that would be 
considered in the first line of therapy.  Specimens for TB were processed separately; 
these results have been reported.[11]   
 
Statistical analysis and Sample size 
For summary statistics, continuous variables are expressed as medians (interquartile 
range, IQR). Categorical variables are expressed as number (percentage).  
 
Risk ratios were used to compare mortality proportion of children who had ever had a 
bacteraemia to those who did not have bacteraemia.  Crude rates of bacteraemia 
between the two dosing schedules and across time-varying age and HAART 
exposure categories were compared by dividing the number of bacteraemias 
observed by the person-time accrued in each category.  Age was dichotomised at 12 
months; HAART was categorised as (1) not on HAART, (2) on HAART for less than 3 
months (at high risk for immune reconstitution inflammatory syndrome) or (3) more 
than 3 months on HAART.  Follow-up time was calculated from enrolment to last 
known time alive.   
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The main outcome measure for multivariate analysis was number of episodes of 
bacteraemia.  The main exposure variable was dosing schedule (comparing 
intermittent to daily CPT, using intention to treat analysis).  Counts of bacteraemia 
over 5 years were modelled using a negative binomial model, after comparing 
different count models (Poisson, zero inflated Poisson) with the Vuong statistic, and 
with Akaikes Information Criterion (AIC).[13] As some patients had repeated 
episodes, we adjusted for potential within-individual correlation by using generalised 
estimating equations (GEE), clustering on each child.[14] 
   
Baseline characteristics that were explored included age, sex, dosing schedule, 
INH/placebo allocation, nutrition status (weight-for-age, weight-for-height and height-
for-age Z-scores), study site, CD4 count, CD4 percentage at baseline, and WHO 
clinical stage at baseline. Age and exposure to HAART were included as categorical 
time-varying covariates. Variables associated with the outcome at the α=0.1 level 
were included for multivariate analysis.  Manual and automated backwards and 
forwards step-wise model building procedures were used; potential models were 
compared with the AIC. The final model chosen presented the best AIC value and 
included study site, dosing schedule, weight-for-age Z-score, WHO clinical category, 
age and HAART exposure category. 
 
Z scores were calculated according to the World Health Organization Standard 
Growth Charts[12] using Epi-Info statistical program, and then saved in the data 
base.  Subsequent analyses were done in STATA statistical software, version 10 
(StataCorp LP, College Station, Texas, USA). All p-values are two-tailed.  
 
Sample size 
The a priori defined study sample size was 400; this sample size was primarily 
determined by the expected mortality effect of INH compared to placebo[11]. Due to 
the early and significant mortality difference in the INH/placebo comparison, study 
enrolment was terminated before this sample size was achieved.  Therefore all our 
findings are presented with 95% confidence intervals which reflect the precision 
achieved by the realised sample size of 324 individuals (47 events).  
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Results 
Baseline characteristics 
Three hundred and thirty nine children were enrolled; fifteen children were excluded 
(ten tested HIV-negative, five were lost to follow-up within a month after 
randomisation), figure 1. Therefore, 324 children (181 males (56%)) were followed for 
672.1 child years (interquartile range (IQR) 1.03 to 4.04 years). 28 (9%) children 
were lost to follow-up and 38 (11.7%) withdrew on personal request or relocated. The 
median age at enrolment was 23 months (IQR 9.5 to 48.6 months); 98 children 
(30.3%) were less than 1 year old. One hundred and sixty five (50.9%) children were 
randomised to three times per week CPT, while 159 (49.1%) were randomised to 
daily, table 1.  
 
One hundred and twenty three (38%) children were underweight for age at enrolment  
(Z score of  less than -2); the median weight-for-age Z score was -1.5.   Most had 
moderate to severe immune suppression: 271 (84%) were either WHO clinical 
category 3 or 4. Median CD4 percentage was 20% (IQR 13.6 to 26.9%). Although 
only 28 (12%) were on HAART at enrolment, a further 179 (55%) started HAART 
during follow-up, table 1.  Adherence to study medication was excellent.[15] 
 
Blood stream infections 
Three hundred and sixty four blood cultures were taken from 125 children; 77 
children had more than 1 blood culture taken.  There were 27 contaminants (8%); 2 
cultures grew Candida species and 288 cultures (80%) had no growth after 5 days.  
Forty-seven bacteraemias occurred in 30 children; 8 children had more than one 
bacteraemia.  Twenty-five (53%) pathogens were Gram negative while 22 (47%) 
were Gram positive bacteria.  Of the 47 bacteraemias, 14 (30%) occurred more than 
72 hours after admission to hospital (7 Enterobacteriaceae, 2 Haemophilus sp, 2 
Pseudomonas sp, 2 S aureus and 1 S. pneumoniae).  Haemophilus influenzae type 
B was not detected. Streptococcus pneumoniae was the most common single 
isolate, occurring in one-third of all positive cultures, table 2.   
 
Antimicrobial resistance patterns were available for 45 bacteria; 7 (58%) of the 12 
Enterobacteriaceae produced extended spectrum beta-lactamase (ESBL).   Five of 
these isolates were also resistant to gentamicin; one K.pneumoniae was also 
resistant to amikacin. Of the S. pneumoniae, 7 of the 14 (50%) isolates showed 
reduced susceptibility to penicillin (MIC >0,06 ug/ml); one was also resistant to 
cefotaxime (MIC 4.0 ug/ml). All 5 Staphylococcus aureus isolates were resistant to 
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CTX; 4 (80%) were methicillin resistant (MRSA).  Of 30 bacteria tested against CTX, 
25 (83%) were resistant, table 2.  There was no significant difference in CTX 
resistance in bacteria cultured from patients randomised to intermittent versus daily 
CPT.  Ten (77%) of 13 bacteria isolated from children receiving daily prophylaxis 
were resistant to CTX, compared to 32 (94%) of 34 bacteria from children receiving 
intermittent prophylaxis (risk ratio 0.74, 95% CI 0.45 – 1.19).   
 
Mortality 
Fifty three of 324 children (16%) died.  Children with an episode of bacteraemia had 
higher mortality than those without bacteraemia: 13/30 (43%) with bacteraemia died 
versus 40/294 (14%) without bacteraemia (risk ratio for mortality 3.18, 95% CI 1.93 to 
5.25). Of the 13 children who died, 4 (31%) had Gram positive and 9 (69%) had 
Gram negative bacteraemia.  Five (38%) of the 13 deaths occurred within 14 days of 
a bacteraemia; all of these deaths were due to clinical sepsis.  Two (40%) of these 5 
deaths were related to a resistant pathogen (both due to ESBL-producing Klebsiella 
pneumoniae).  As reported, mortality was similar among children receiving 
intermittent CPT (24 of 165, 14%) compared to daily CPT (29 of 159, 18%; hazard 
ratio 0.75 95% CI 0.44-1.29).[10] 
 
Characteristics of children with bacteraemia 
Children randomised to intermittent CPT had more episodes of bacteraemia than 
those randomised to daily CPT. Nineteen children from the intermittent group had 34 
bacteraemias (6 had recurrent infections, crude incidence rate (IR) 9.6 per 100 
person-years), compared to 11 children from the daily group, who had 13 
bacteraemias (2 had recurrent infections, crude IR 4.08 per 100 person years; 
incidence rate ratio (IRR) for bacteraemia 2.36, 95% CI 1.21 – 4.86, table 3). There 
were significantly more episodes of Gram negative bacteraemia in children receiving 
intermittent compared to daily prophylaxis [20 (80%) vs. 5 (20%), IRR 3.61 (95% CI 
1.31 – 12.3)].  There was also a trend towards more Gram positive bacteraemias in 
the intermittent [14, (64%)] compared to the daily group [8, (36%)], (IRR1.58, 95% CI 
0.62-4.34).  
 
Prior to the termination of the placebo arm of the trial in May 2004, there was no 
difference in the number of children who had bacteraemia while receiving INH (9 of 
131) compared to placebo (9 of 132), risk ratio 1.03 (95% CI 0.43 – 2.53). 
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Twenty-six (55%) of the 47 bacteraemias occurred in children not on HAART; 14 
(30%) occurred within 3 months after starting HAART (crude IRR compared to 
children not on HAART 3.82, 95% CI 1.84 – 7.58) while only 7 (15%) occurred once 
established on HAART for more than 3 months (crude IRR compared to children not 
on HAART 0.26, 95% CI 0.09 – 0.61), table 3. 
 
Bacteraemia was more common in infants and young children than in older children 
(median age at bacteraemia 18 months, IQR 10.5 to 37.5 months).  There were 15 
(32%) bacteraemias in children aged less than 12 months; 14 (93%) were due to 
Gram negative bacteria.  There were 21 (45%) bacteraemias in the second year of 
life (8 (38%) due to S. pneumoniae); and 11 (23%) bacteraemias in children older 
than 2 years, 7 (64%) due to S. pneumoniae.    
 
Risk factors for bacteraemia  
In the multiple regression model (negative binomial) controlling for the effects of age, 
study site, HAART status and degree of immune suppression, children receiving 
intermittent CPT had a higher incidence rate of bacteraemia than daily CPT (IRR 
2.33, 95% CI 0.87 – 6.24), table 4. Children recently started on HAART had a two-
fold increased incidence rate of bacteraemia compared to those not on HAART (IRR 
2.25, 95% CI 0.87 – 5.87), whereas children established on HAART had a 
significantly decreased incidence rate compared to children not on HAART (IRR 
0.18, 95% CI 0.04 – 0.83).  Weight-for-age at enrolment remained a strong predictor 
for bacteraemia, with a 30% decreased incidence rate of bacteraemia with every unit 
increase in Z score, table 4. 
 
Discussion 
In this study of HIV-infected children, malnutrition, young age and lack of HAART 
were risk factors for bacteraemia.  Novel findings were increased incidence of 
bacteraemia when CPT was given thrice-weekly compared  to daily, and a higher 
incidence of bacteraemia in children in the first months after commencing HAART, 
with the incidence substantially reduced once HAART was established.  
 
The observed pre-HAART incidence rate of 8.5 bacteraemias per 100 person-years 
is similar to rates reported from other pre-HAART studies of bacteraemia in HIV-
infected children of similar age.  As bacteraemia is more common in younger 
children, the studies that included older children and teenagers[7, 16] had lower 
incidence rates (2.8 and 3.3 per 100 person-years) than when follow-up was 
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censored at 72 months of age (9.8 per 100 person-years)[2]. The highest incidence 
rate (23 per 100 person years) was observed in a small cohort of young children 
followed from birth to 36 months, less than half of whom were receiving CPT.[17]   
 
Four studies have reported 70 to 89% decreases in incidence rates of bacteraemia in 
children after starting HAART.[2, 6, 7, 18]  The magnitude of decreased incidence 
rate ratio was similar irrespective of whether infants, children or teenagers were 
included in the analysis.  This is consistent with the highly significant 83% reduction 
in adjusted incidence rate ratio observed in this cohort. 
 
Increased incidence of bacteraemia during the first 3 months after starting HAART 
was observed.  As the allocation to HAART was not randomised but based on clinical 
need, a higher incidence of bacteraemia in the first 3 months may reflect that starting 
HAART in this context was a marker of disease severity, and children with the most 
advanced disease had the highest risk of bacteraemia. The effect of HAART in 
restoring immunity may take months to years in children with severe immune 
suppression; these children would still be highly susceptible to infection in the first 3 
months after initiating HAART.  The significant reduction in bacteraemia after 3 
months of HAART reflects the expected overall beneficial effect on immune function 
and decreased susceptibility to infection [5] and is consistent with previous studies. 
 
Increased incidence of bacterial infections has previously been described soon after 
starting HAART in severely immune suppressed children.  In a study of the incidence 
of pneumococcal disease in HIV-infected children in Philadelphia, USA, a 14% 
increase in cases of invasive pneumococcal disease was observed in the “transition 
year” as children were started on HAART.[18]  In a cohort in Thailand, 35% of 
children needed hospital admission after starting HAART; 62% of the admissions 
were for “pneumonia and other bacterial infections”.[19]   Immune reconstitution 
inflammatory syndrome (IRIS) has been well described in children;[20] common 
manifestations are muco-cutaneous eruptions and exacerbation or unmasking of 
tuberculosis.[21]   Consensus criteria for definition of an IRIS event state that 
“symptoms cannot be explained by an alternate infection.”[22]  However, in a cohort 
of Ugandan children, 6.5% of IRIS events were attributed to bacterial pneumonia,[23] 
and S. pneumoniae sepsis with empyema and bacteraemia was described in a case 
from a paediatric study in South Africa.[24]  
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Daily CPT compared to placebo has been shown to decrease mortality of HIV-
infected African children,[8] with significant reductions in bacterial infections.[9]   It 
has previously been reported that daily CPT provides better protection against 
bacteraemia than intermittent CPT and is associated with decreased duration of 
hospitalisation.[10]   A multicentre study among HIV-infected adults in the USA 
showed that daily CPT was associated with an 18% decreased incidence of bacterial 
pneumonia compared to thrice weekly CPT, but did not report the incidence of 
bacteraemia or a difference in incidence of Gram positive and Gram negative 
infections.[25]   
 
The higher incidence of bacteraemia observed among children receiving intermittent 
CPT was predominantly due to Gram negative organisms.   It is possible that there is 
a different threshold for protection from Gram negative and Gram positive 
bacteraemia, although the numbers are small.  We postulate that intermittent CPT 
provided some protection against Gram positive infections, and there was additional 
benefit when CPT was given daily.  However intermittent CPT provided inadequate 
protection against invasive Gram negative infections, but daily CPT was effective, 
resulting in a significant 3-fold decreased incidence of bacteraemia. 
 
S pneumoniae, the most common pathogen, is a frequent cause of invasive disease 
in HIV-infected children. [3, 26]  In South Africa, the highest incidence of invasive 
pneumococcal disease (IPD) occurs in children under 1 year,[27] but S. pneumoniae 
bacteraemia was only detected in children older than 1 year.  It is possible that CPT 
is more effective at preventing IPD in infants than in older children.   This trial was 
completed before the launch of the pneumococcal conjugate vaccine in South Africa. 
It is anticipated that with inclusion in the national immunisation schedule, substantial 
morbidity and mortality may be prevented in HIV-infected children.[28]    
 
The vaccination schedule remained constant throughout the duration of the trial, and 
included 3 doses of Haemophilus influenzae type B conjugate vaccine.  Although this 
vaccine has been shown to have up to 35 times increased risk of vaccine failure in 
HIV-infected children in South Africa compared to HIV-uninfected children,[29] there 
was still some degree of protection, as no isolates of Haemophilus influenzae type B 
were isolated. 
 
No Salmonella sp were detected in this cohort.    Non-typhi Salmonella were 
occasional bloodstream pathogens in previous studies among children in Cape 
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Town; prevalence of CPT was not reported.[30-32]  Many studies from East or 
central Africa report a high incidence of both S. typhi and non-typhi strains, even 
among children receiving CPT, [1, 9] as well as high incidence of CTX-resistant 
Salmonellae.[1, 9, 33, 34]  In South Africa, 19% of non-Typhi Salmonella are 
resistant to CTX.[27]  It is possible that CPT provides in vivo protection from invasive 
disease despite in vitro CTX resistance.[35]   
 
High prevalence of antibiotic resistance was observed.  There are several possible 
contributing factors.  Firstly, HIV-infected children are known to be colonised with 
resistant organisms, as was shown by a high prevalence of colonisation with MRSA 
and ESBL-producing-Enterobacteriaceae in nasopharyngeal cultures at baseline in 
this cohort.[36]  It has been suggested that antibiotic resistance is common among 
the families and communities of the study population, and that many young infants 
may be colonised with resistant organisms even before they are admitted to 
hospital.[36] Secondly, some children were enrolled soon after a hospital admission, 
where they may have acquired resistant organisms;  the frequency and length of 
hospitalizations  in which colonisation with hospital flora may have occurred has been 
described[10].  Thirdly, high levels of antibiotic resistance have been described 
among children with severe malnutrition admitted with pneumonia[37] and many of 
the children in this cohort were also malnourished.   
 
The negative binomial regression is a more robust method for modelling count data 
than Poisson regression, but gives more conservative confidence intervals.[13]  
When comparing intermittent to daily CPT, the univariate (unadjusted) incidence rate 
ratio from the regression model had a similar point estimate (2.36) to the crude 
incidence rate ratio (2.44) which was calculated by dividing the number of 
bacteraemias by the person time in each prophylaxis group.  However the IRR from 
the regression model is not statistically significant due to the conservative nature of 
the model.  It is interesting that in the multivariate model, after adjusting for age, 
WHO clinical stage, degree of malnutrition and HAART status, the point estimate and 
confidence intervals did not change.  This implies that the protective effect of daily 
CPT is independent of these other factors, and clinical benefit can be anticipated at 
all ages and degrees of immune suppression and malnutrition   
 
There are a number of limitations to this study.  Blood cultures are known to be 
insensitive in detecting bacterial disease.[38]  Furthermore, the blood cultures 
obtained for our study were taken for clinical indications and not routinely, possibly 
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under-representing the true incidence of bacteraemia in this population.  Only those 
children brought to hospital could have had blood cultures taken, so those who died 
at home were excluded. However, only 5 children died outside a hospital facility.[11]  
Treatment with antibiotics by a primary-care provider before referral may have further 
decreased the detection rate; it was not possible to objectively measure antibiotic use 
prior to hospitalisation.  As cultures were taken by different clinical care providers and 
not by members of the study team, there may have been varying techniques, and 
different volumes of blood taken.  The high number of contaminants indicates that 
despite availability of standard guidelines, sterile technique is frequently not possible 
in the emergency room.  Some of the contaminants may have masked pathogenic 
organism growth, which would also lead to an under-estimate of incidence.  For 
these reasons, our estimate of 7.0 bacteraemias per 100 person-years is almost 
certainly an underestimate. 
 
Conclusion 
Bacteraemia in HIV infected children is common, is predominantly due to common 
organisms such as S pneumoniae, and is associated with high mortality. Effective 
preventative measures such as pneumococcal vaccines, daily CPT and HAART 
should urgently be scaled up for HIV-infected children in Africa.    
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Table 1:  Comparison of children assigned to intermittent or daily trimethoprim-
sulphamethoxazole prophylaxis regimens at randomisation 
 
Intermittent  
(n=165) 
Daily  
(n=159) 
Total  
(N=324) 
Age (months):     
Median  21.8(9.5 – 52.3) 24.6(9.7 – 45.6) 23.0(9.5 – 48.6) 
<12 months  29.7% (49) 30.8% (49) 30.3% (98) 
>12 months  70.3% (116) 69.2% (110) 69.8% (226) 
Male  56.9% (94) 54.7% (87) 55.8% (181) 
Weight for age (z-score)  -1.3(-1.8 to -1.0) -1.6(-1.9 to -1.2) -1.5(-1.8 to -1.2) 
Weight for height (z-score)  -0.23(-0.41 to -0.10) -0.24(-0.47 to -0.02) -0.24(-0.38 to -0.02) 
Height for age (z-score)  -1.90 (-2.65 to -0.76) -1.91 (-2.79 to -1.02) -1.95 (-2.76 to -0.94) 
World Health Organisation Clinical Staging   
1 or 2 28 25 53 
3 99 95 194 
4  38 39 77 
CD4 (% lymphocytes)  20.4(14.3 – 28) 19.0(12.1 – 25.2) 19.96(13.6 – 26.9) 
On HAART: 
      At enrolment  
      Total received HAART 
      during study period 
 
8.5% (14) 
 
63.0% (104) 
 
8.8% (14) 
 
64.8% (103) 
 
8.6% (28) 
 
63.9% (207) 
 
 
Figures are medians (interquartile range) for continuous variables, or percentage (number) for 
categorical variables 
HAART, highly active antiretroviral therapy 
No P-values for pairwise comparisons of baseline characteristics at randomisation were significant
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Table 2:  Pathogenic bacteria and antimicrobial resistance. 
 
Pathogens 
 
 
Number (%)  
(N=47) 
 
Number resistant to selected antibiotics 
/ Total number tested (%) 
 
Gram Positive 
  
      S. pneumoniae 15 (32 %) CTX - 2/2 (100%) 
Penicillin / Ampicillin - 7/14 (50%) 
Erythromycin - 2/9 (22%) 
Cefotaxime - 1/10 (10%) 
     S. aureus 5 (11 %) CTX - 5/5 (100%) 
Cloxacillin  - 4/5 (80%) 
Vancomycin - 0/5 
Ciprofloxacin - 0/5 
Clindamicin - 0/5 
Erythromycin - 4/5 (80%) 
      Group G streptococcus 1 (2 %) Penicillin - 0/1 
     Streptococcus sanguinis 1 (2 %) Penicillin - 0/1 
Total Gram positive 22 (47%)  
 
Gram negative 
  
      Enterobacteriaceae *  CTX – 11/13 (85%)  
Gentamicin 7/11 (64%)  
Amikacin 1/12 (8%) 
Ceftriaxone** – 7/12 (58%) 
Ciprofloxacin – 2/10 (20%) 
Imipenem / Meropenem - 0/9 
* Antibiotic resistance for Enterobacteriaceae 
shown for group, not individual organisms 
**Resistance to ceftriaxone denotes ESBL 
production  
      Klebsiella sp 7 (15 %) 
      Citrobacter freundii 2 (4 %) 
      E. coli 3 (6 %) 
      Enterobacter cloacae 1 (2 %) 
      Shigella flexneri 1 (2 %) 
 43 
 
Pathogens 
 
 
Number (%)  
(N=47) 
 
Number resistant to selected antibiotics 
/ Total number tested (%) 
Other Gram Negative   
      Acinetobacter sp 4 (9 %) 
CTX 2/4 (50%) 
Gentamicin 0/4 
      Campylobacter species 1 (2 %) 
Ceftriaxone 0/1 
Ciprofloxacin 1/1 (100%)** 
      Gram negative bacillus 1 (2 %) 
CTX 0/1 
Ceftriaxone 0/1 
      Haemophilus influenzae 3 (6 %)   
CTX– 3/3 (100%) 
Ampicillin - 0/3 
      Pseudomonas aeruginosa 2 (4%) 
CTX  - 2/2 (100%) 
Amikacin 1/2 
Ceftazidime - 1/2  (50%) 
Piptazobactam 0/2 
Meropenem – 0/2 
Total Gram negative 25 (53%)  
Total 47 (100%)  
* Antibiotic resistance for Enterobacteriaceae shown for group, not individual organisms 
** Sensitivity test for Campylobacter based on laboratory-specified criteria 
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Table 3:  Incidence rates* of bacteraemia by prophylaxis regimen, age category and HAART exposure time.   
 
Person time 
(person years) 
Number of 
bacteraemias 
Incidence Rate (per 
100 person-years) 
Incidence rate ratio 
(95% CI) 
p-value 
HAART exposure:       
    Not on HAART 306.3 26 8.5 1 - 
   ≤ 3 months on HAART 43.2 14 32.4 3.82  (1.84 – 7.58) 0.0002 
   > 3 months on HAART 321.9 7 2.2 0.26 (0.09 – 0.61) 0.0005 
Age:      
     < 12 months 30.47 15 49.23 1  
     ≥ 12 months 640.86 32 4.99 0.10 (0.05 – 0.20) <0.0001 
Prophylaxis regimen:      
   Daily 318.31 13 4.08 1  
   Thrice weekly 353.02 34 9.63 2.36 (1.21 – 4.86) 0.006 
Total study 671.33 47 7.00 - - 
* Rates are unadjusted crude rates calculated by number of bacteraemias over exposure time 
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Table 4:  
Incidence rate ratio of bacteraemias: unadjusted and adjusted, from negative binomial regression 
 Unadjusted 
Incidence Rate 
Ratio 
95% CI p-value 
Adjusted 
Incidence 
Rate Ratio* 
95% CI p-value 
Prophylaxis 
regimen:  
      
 Daily 1 -  1 -  
 Intermittent 2.44 0.92 – 6.46 0.07 2.33 0.87 – 6.24 0.09 
Age:       
  Age <12 months 1   1   
  Age ≥12 months 0.23 0.08 – 0.63 0.005 0.16 0.05 – 0.48 0.001 
HAART exposure:       
Not on HAART 1   1   
HAART <3 months 1.30 0.47 – 3.66 0.61 2.25 0.87 – 5.87 0.10 
HAART >3 months 0.10 0.02 – 0.43 0.002 0.18 0.04 – 0.83 0.03 
Weight-for-age Z 
score 
0.51 0.36 – 0.74 <0.0001 0.70 0.49 – 1.02 0.06 
* Adjusted for study site and WHO clinical category at enrolment  
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Children randomised 
(n=339) 
Allocated to Daily  
(n=91) 
Allocated to 3xWeek  
(n=84) 
Allocated to Daily  
(n=80) 
Allocated to 3xWeek  
(n=84) 
Tygerberg Children’s Hospital (n=164) Red Cross Children’s Hospital (n=175) 
Did not have HIV (n=3) 
Lost to follow up (n=1) 
  
 
Did not have HIV (n=0) 
Lost to follow up (n=1) 
  
Did not have HIV (n=5) 
Lost to follow up (n=3) 
Did not have HIV (n=2) 
Lost to follow up   (n=0) 
  
Analyzed (n=87) 
 
Analyzed (n=83) 
 
Analyzed (n=72) 
 
Analyzed (n=82) 
Alive (n=43) 
Died (n=19) 
Lost to follow up (n=9) 
Withdrew from study (n=16) 
 
 Relocated (n=7) 
 Maternal request (n=3) 
 Started HAART (n=5) 
 Other (n=1) 
 
Alive (n=47) 
Died (n=17) 
Lost to follow up (n=5) 
Withdrew from study (n=14) 
 
 Relocated (n=8) 
 Maternal request (n=4) 
 Started HAART (n=1) 
 Other (n=1) 
 
Alive (n=51) 
Died (n=10) 
Lost to follow up (n=7) 
Withdrew from study (n=4) 
 
 Relocated (n=1) 
 Maternal request (n=1) 
 Started HAART (n=1) 
 Other (n=1) 
 
Alive (n=64) 
Died (n=7) 
Lost to follow up (n=7) 
Withdrew from study (n=4) 
 
 Relocated (n=2) 
 Maternal request (n=2) 
 Started HAART (n=0) 
 Other (n=0) 
 
Allocated to 
INH prior to 
May 2004 
(n=31) 
 
 
Allocated to 
INH prior to 
May 2004 
(n=38) 
 
 
 
 
 
 
Allocated to 
INH prior to 
May 2004 
(n=39) 
 
 
Allocated to 
placebo prior 
to May 2004 
(n=30) 
 
Allocated to 
placebo prior 
to May 2004 
(n=41) 
 
Allocated to 
placebo prior 
to May 2004 
(n=37) 
 
Allocated to 
INH prior to 
May 2004 
(n=31) 
 
 
Allocated to 
placebo prior 
to May 2004 
(n=30) 
 
Allocated to INH after May 
2004 
(n=5) 
Allocated to INH after May 2004 
(n=4) 
Allocated to INH after May 2004 
(n=23) 
Allocated to INH after May 2004 
(n=30) 
Fig 1. Trial flow 
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Response to examiner’s comments: 
 
A) Literature review: 
 
1) Reviewer 1: 
Background  
Comment that bacteraemia is the most extreme form of invasive form of infection has 
been removed 
References to basic immunology have been revised 
Comment on vaccine effectiveness in HIV infected children and vaccine coverage in 
Africa added. 
Objectives  
Objectives have been revised to be more realistic 
Search strategy 
Child defined as less than 18 years 
Reference to low-HIV preference studies omitted 
The incidence of bacteraemia in children recently started on cART was not a major 
objective of the literature review, as this would have involved an extensive review of 
immune reconstitution inflammatory syndrome in children and adults.  Thus the main 
focus of the literature review was on the incidence of bacteraemia in HIV-infected 
children in Africa, with a short description of the decreased incidence of bacteraemia post 
starting cART. 
Results 
Each study is listed and described in the table, and salient point elaborated on in the 
discussion.  
Discussion 
Ambiguous references to “sepsis” have been removed 
References 
References have been re-formatted 
 
2) Reviewer 2: 
Abbreviations have been explained, inconsistencies revised 
Table re-formatted so that one row is not split over 2 pages 
Comments 
1) Total of bacteraemias revised to 919 (not 949) 
2) a) Description of incidence rates in Berkley’s study amended to rates per 100 000 
persons per year, not person-years 
b) Incorrect use of “mortality” replaced by “case fatality ratio” throughout 
3) Discrepancy between number of HIV-infected children in a study and number of  
bacteraemias observed is due to recurrent bacteraemias: some children had more than one 
episode of bacteraemia.  Table 1 Column heading changed to “Number of bacteraemias” 
and explanation to this effect added to results 
4) Case fatality ratios (and the numbers they were derived from) have been added to the 
last column.  
5) Comment on sickle cell disease and predisposition to bacterial infection added to 
“Search strategy” 
 
2) Research article: 
 
Reviewer 1: 
1) Introduction: 
 Impact of HAART on mortality now includes comment on clinical trial as well as 
programmatic settings, and effectiveness of HAART among African children; 
added extra references. 
 Effectiveness of blood culture to detect bacteraemia are addressed in the 
discussion 
 Vaccination schedule and response among HIV infected children addressed in 
discussion 
 
2) Methods 
 General: Inconsistent use of Tygerberg Children’s Hospital corrected 
 Medication: Exact dose of CTX on each regimen clarified. 
 Bacteriology:   
o Added statement that cultures were taken on treating clinician’s discretion 
o Concept of “secondary level hospital” clarified in the text; 
o Explanation given for choice of antibiotics   
o Description about decision to classify bacteria as contaminants vs 
pathogens added. 
 Statistical analysis 
o Description of Z scores and references added. 
o CDC immune staging replaced with WHO clinical staging 
3) Results: 
 Baseline characteristics:  
o Statement about children being under weight (for age) has been corrected 
and qualified. 
o CDC immune staging replaced with WHO clinical staging  
 Table 1:  
o Changed title to “Comparison of children assigned to intermittent or daily 
trimethoprim-sulphamethoxazole  prophylaxis regimens at randomization” 
o CDC clinical staging replaced with WHO clinical staging  
o CDC immune staging removed from Table 1 
o Comment regarding a comparator statistic (p value) to illustrate lack of 
difference in two groups at randomization has been added to table 1.  
 Bloodstream infections: 
o Results of resistance testing re-phrased so that Pseudomonas is not 
confused with the Enterobactereacea. 
o Comment added regarding absence of Haemophilus influenzae type B 
 
 
Table 2: 
o ESBL-producing Enterobacteriacea identified in the table  
 Mortality 
o Comment added regarding cause of death in children who died soon after 
bacteraemia 
o Sensitivity of blood culture to detect invasive bacterial disease is 
addressed in the discussion 
 Predictors of bacteraemia  (Paragraph title changed to “Risk factors for 
bacteraemia”) 
o Possibility that bacteraemia may be a form of IRIS is discussed in the 
discussion 
 Table 4 
o Replaced CDC immune category with WHO clinical category; 
recalculated the adjusted incidence rate ratios. 
4) Discussion 
 Comment added regarding unexpected low incidence of S. pneumoniae 
bacteraemia in children aged <1 year 
 Comment added on difference in incidence of Gram negative and Gram positive 
bacteraemia. 
 Comment added regarding absence of H influenzae type B and response to 
vaccination with Hib conjugate vaccine 
 Comment added regarding antibiotics and prescribing practice. 
 The incidence of hospitalisation in 1st three months after starting HAART has 
been addressed in other publications; a detailed description of immune 
reconstitution inflammatory syndrome and the incidence of hospitalization is not 
within the scope of this article. 
 
5) References 
 Formatting revised. 
 
2) Reviewer 2 
 
1) Number of blood cultures, no growth, contaminant and bacteraemia corrected 
2) Number of penicillin-resistant pneumococcus corrected; definition of resistance 
(penicillin MIC) added 
3) Characteristics of children with bacteraemia 
 Sentence regarding Gram positive bacteraemias in the different prophylaxis 
groups rephrased: there is non-significant trend towards increased bacteraemias in 
children receiving intermittent therapy  
 Paragraph regarding age-related incidence of bacteraemia clarified, and incidence 
of S pneumoniae explained. 
4) Table 2: comment regarding sensitivities of Enterobacteriaceae moved to be on 
same page as the antibiotic descriptions. 
5) Influence of INH on bacteraemia: top of page 9 – there was no difference between 
the placebo and the INH groups. 
6) Collaborators named and their contributions identified 
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scanned images must have a resolution of at least 300 dpi. If fonts 
are used in artwork, they must be converted to paths or outlines or 
they must be embedded in the files. Please note that artwork 
generated from office suite programs such as Corel Draw and MS 
Word and artwork downloaded from the Internet (JPEG or GIFF 
files) cannot be used. When preparing charts and graphs, authors 
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